Loading...
Skip to content
get in touch

Publications & Presentations

Dr Clare Hague publishes numerous peer-reviewed articles and poster presentations each year across a variety of noteworthy journals and conferences.

Textbook Chapters (maiden name Hibbert)

  • Hibbert CL, Edbrooke DL. Economic Outcomes. Outcomes in Critical Care Editors S Ridley and D Young. Publishers Butterworth Heinemann. Published Jan 2002.
  • Edbrooke DL, Hibbert CL, Jacobs P. Health Economics of Intensive Care. Yearbook on Intensive Care and Emergency Medicine. Series Editor: J. L Vincent. Publishers: Springer-Verlang. March 1999.
  • Edbrooke DL, Hibbert CL. Fungal Infections in the ICU – Disease Management Monograph. Chapter 8 – Pharmacoeconomics of anti-fungal therapy in the ICU. In association with The Liposome Company.

 Journal Articles (maiden name Hibbert)

  1. Edbrooke DL, Hibbert CL, Wilson AJ, Mann AJ, Stevens VG. The cost of individual patient treatments in intensive care. Proceedings from the 3rd. World Conference of Surgical Efficiency & Economy. Kiel Sept 13-15 1995.
  2. Edbrooke, DL, Hibbert CL, Wilson AJ, Mann AJ, Stevens VG. A first evaluation into the costing of intensive care patients. 8th European Congress of Intensive Care Medicine. II Free Papers. 1995. Athens October 18-22 1995.
  3. Edbrooke DL, Stevens VG, Wilson AJ, Hibbert CL, Kingsley J, Mann AJ. The Provision of High Dependency Units in England – The Cost and Benefits of Development and Implementation. Intensive Care Medicine 1996;2:S3.
  4. S Smith, V G Stevens, A J Wilson, C Hibbert, A Mann, D L Edbrooke. Cost Implications for ICUs of the Ageing Population. Intensive Care Medicine 1996;2:S3.
  5. Stevens VG, Edbrooke DL, Hibbert CL, Wilson AJ. Integrated Clinical and Cost Audit in the ICU. Current Perspectives in Healthcare Computing Conference, Harrogate (7-9th March 1997) Published in Conference Proceedings.
  6. Edbrooke DL, Stevens VG, Hibbert CL, Mann AJ, Wilson AJ. A new method of accurately identifying costs of individual patients in intensive care: the initial results. Intensive Care Medicine 1997: 23:645-650.
  7. Edbrooke DL, Stevens VG, Hibbert CL, Kingsley JM, Smith S, Wilson AJ. High dependency units in England – The lack of provision and the cost of addressing the shortfall. Care of the Critically Ill 1997; 13:6:216-218.
  8. Smith S, Stevens VG, Edbrooke DL, Hibbert CL, Kingsley JM. Impact of the ageing population on intensive care unit provision. Nursing in Critical Care 1997;2:5:239-242.
  9. Edbrooke DL, Hibbert CL, Kingsley JM, Wilson AJ, Stevens VG, Smith S, Loynes RM. The costs of severe sepsis in a UK adult general intensive care unit. Intensive Care Medicine 1997;23:1:S155.
  10. Edbrooke DL, Hibbert CL. A Standardised Method for Costing Adult General Intensive Care Units (ICUs) in the UK. Intensive Care Medicine 1997;23:1:S155.
  11. Hibbert CL, Edbrooke DL. An economic model for evaluating the cost impact of new drug therapies in intensive care patients. Intensive Care Medicine 1997;23:1:S155.
  12. Edbrooke DL, Lindley EJ, Stevens VG, Wilson AJ, Hibbert CL. Which factors can be used to accurately predict the costs of care for intensive care patients? Intensive Care Medicine 1998;24:S58.
  13. Hibbert CL, Edbrooke DL. A cost analysis of ICU patients who receive low-air loss bed therapy and the additional costs involved. Intensive Care Medicine 1998;24:S58.
  14. Mills GH, Hibbert CL, Edbrooke DL. Can TISS be used to accurately reflect the daily costs of care for individual patients on the Intensive Care Unit? Intensive Care Medicine 1998;24:S58.
  15. Edbrooke DL, Hibbert CL, Mills GM. Does it make sense to correlate TISS points to ICU costs? Acta Anaesthesiologica Scandinavica 1998;112:42:195-196.
  16. Stevens VG, Hibbert CL, Edbrooke DL. Evaluation of proposed case-mix criteria as a basis for costing patients in the adult general Intensive Care Unit. Anaesthesia 1998;53:944-950.
  17. Hibbert CL, Edbrooke DL, Corcoran M. Is organ support the answer to costing care in the ICU? Intensive Care Medicine 1999;25:Suppl 1:S170.
  18. Edbrooke DL, Hibbert CL, Ridley S, Long T, Dickie H. The development of a method for comparative costing of individual intensive care units. Intensive Care Working Group on Costs. Anaesthesia 1999;54:110-121.
  19. Hibbert CL, Edbrooke DL, Kingsley JM, Corcoran MC, Bright N. Cost considerations for the use of low-air loss bed therapy in the adult intensive care unit. Intensive and Critical Care Nursing 1999;15:3:154-162.
  20. Edbrooke DL, Hibbert CL, Chalfin D. Cost determination and economic evaluation in critical care. Educational primer published by the European Society of Intensive Care Medicine. October 1999.
  21. Edbrooke DL, Hibbert CL, Kingsley JM, Smith S, Bright NM, Quinn J. The patient-related costs of sepsis patients in a UK adult general intensive care unit. Critical Care Medicine 1999;27:9:1760-1767.
  22. Edbrooke DL, Hibbert CL, Corcoran MC. Costing Methods in Intensive Care. Critical Care Monitor 1999;4:43-47.
  23. Edbrooke DL, Hibbert CL. Cost-Determination and Economic Evaluation in Critical Care. Current Opinion in Critical Care 1999; 5:316-320.
  24. Tolley K, Pang F, Brown M, Hibbert C, Beck E. The value of observational datasets in the economic evaluation of pharmaceuticals. Health Economists’ Study Group Paper, Newcastle, Jan 2000.
  25. Edbrooke DL, Hibbert CL. Cost-effectiveness in Intensive Care. Published by Drager Werke.
  26. Hibbert CL. An economic evaluation of enteral feeds in the ICU. For Novartis Consumer Health (Formulary Pack). Published July 2000.
  27. Edbrooke DL, Corcoran MC, Dean J, Hibbert CL, Coates E, Jacobs P. The costs of intensive care. II International Congress of Critical Care Medicine in the Internet (CIMC 2000).
  28. Hibbert CL, Corcoran MC, Dean J, Edbrooke DL, Coates E, Jacobs P. How much does it cost to survive in the intensive care unit? II International Congress of Critical Care Medicine in the Internet (CIMC 2000).
  29. Coates E, Hibbert CL. A cost-effectiveness study of enteral immune modulating nutrition in intensive care patients. III International Congress of Critical Care Medicine in the Internet (CIMC 2001).
  30. Dean J, Hibbert CL, Edbrooke DL. Variation in expenditure on intensive care in university and non-university hospitals. III International Congress of Critical Care Medicine in the Internet (CIMC 2001).
  31. Hibbert CL, Edbrooke DL, Coates E. Cost-effectiveness of immunonutrition in the critically ill patient. Complete Nutrition 2001;1:1:9-13.
  32. Edbrooke DL, Ridley SA, Hibbert CL, Corcoran MC. Variations in expenditure between adult general intensive care units. Anaesthesia 2001;56:208-216.
  33. Jacobs P, Edbrooke DL, Hibbert CL, Fassbender K, Corcoran MC. Descriptive patient data as an explanation for the variation in average daily costs in intensive care. Anaesthesia 2001;56:643-647.
  34. Edbrooke DL, Corcoran MC, Dean J, Hibbert CL, Coates EJ, Jacobs P. The costs of intensive care. Revista Portugesa de Medicina Intensiva 2001; 10:2.
  35. Hibbert CL, Corcoran MC, Dean J, Edbrooke DL, Coates EJ, Jacobs P. How much does it cost to survive in the intensive care unit. Revista Portugesa de Medicina Intensiva 2001; 10:2.
  36. Hibbert CL, Edbrooke DL. Intensive Care Costs – A Reply. Anaesthesia 2002; 57:2:184.
  37. Hibbert CL, Edbrooke DL, Coates EJ. Development of a discrete event simulation model to predict bed requirements for critical care. Intensive Care Medicine 2001;
  38. Coates EJ, Hibbert CL, Edbrooke DL. A cost-effectiveness study of enteral immune modulating nutrition in intensive care patients. Intensive Care Medicine 2001;
  39. Angus DC, Rubenfeld GD, Roberts MS, Curtis JR, Connors AF, Cook DJ, Lave JR, Pinsky MR, Cohen IL, Edbrooke DL, Jacobs P, Lambrinos J, Miranda D, Hibbert C, Cook DJ, Linde-Zwirble WT, Moreni R, Tsevat J, Chalfin DB, Hlatky M, Kamlet MS, Roberts MS, Sonnenberg FA, Asch D, Morreim EH, Lave JR, Rie M. Understanding costs and cost-effectiveness in critical care – Report from the Second American Thoracic Society Workshop on Outcomes Research. American Journal of Respiratory and Critical Care Medicine 2002;165:4:540-550.
  40. Jegers M, Edbrooke DL, Hibbert CL, Chalfin DB, Burchardi H. Definitions of cost assessment: an intensivist’s guide. Intensive Care Medicine 2002; 28: 1279-5.
  41. Hibbert CL, Coates EJ, Edbrooke DL. SOLUTIONS SPOTLIGHT. A model to predict bed provision for critical care. International Hospital Equipment and Solutions, February/March 2002;1:30.
  42. Hibbert CL. A systematic review of ICU costs. Hospital, March 2002. Hospital is a bi-monthly journal produced by the European Association of Hospital Managers.
  43. Hibbert CL, Morris J, Partridge S. Funding Critical Care. The Journal of the Intensive Care Society; 2003:4:1: 9-10.
  44. Hibbert CL, Coates EJ. Methodological issues in studies reporting the costs of sepsis patients. Care of the Critically Ill 2004;20:6:167-176.
  45. Hibbert CL, Coates EJ, Brazier JE. A cost survey of 70 adult critical care units: results from a volunteer sample in England, Scotland and Northern Ireland. Care of the Critically Ill 2004;21:1:8-17.
  46. Peek GJ, Clemens F, Elbourne D, Firmin R, Hardy P, Hibbert C, Killer H, Mugford M, Thalanany M, Tiruvoipati R, Truesdale A, Wilson A. CESAR : conventional ventilatory support vs. Extracorporeal membrane oxygenation for severe respiratory failure. BMC Health Services Research 2006 ; 6:163.
  47. Thalanany M, Mugford M, Hibbert C, Cooper N, Truesdale A, Robertson S, Tiruvoipati R, Elbourne D, Peek G, Clemens F, Hardly P, Wilson A on behalf of the CESAR Trial Group. Methods of data collection and analysis of the economic evaluation alongside a national, multicentre trial in the UK: Conventional ventilation or ECMO for severe adult respiratory failure (CSEAR). BMC Health Services Research.
  48. Hibbert CL, Piedra PA, McLauren KK, Vesikari T, Mauskopf J, Mahadevia PJ. Cost-effectiveness of live-attenuated influenza vaccine, trivalent in preventing influenza in young children attending day-care centres. Vaccine 2007.
  49. Bhalla S, Hibbert C, Watkins J, Beard S, Chetty M, Arellano J. To determine the cost-effectiveness of pemetrexed (PEM) compared to current standards of care in 2nd-line advanced non-small cell lung cancer (NNSCLC) from the UK National Health Service (NHS) perspective. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part 1, Vol, 25 No. 18S (June 20 Supplement), 2007:6540.
  50. Bhalla S, Hibbert CL, Chetty M, Poole C, Miles D, Coleman R, Bruce G, Beard S, Watkins J. An evaluation of the clinical and cost-effectiveness of combination chemotherapy with gemcitabine plus paclitaxel for the treatment of Metastatic Breast Cancer (MBC) in the UK from an NHS perspective. 29th Annual San Antonio Breast Cancer Symposium. Abstract Number: 550904.
  51. Peek GJ, Elbourne D, Mugford M, Tiruvoipati R, Wilson A, Allen E, Clemens F, Firmin R, Hardy P, Hibbert C, Jones N, Killer H, Thalanany M, Truesdale A. Randomised Controlled Trial of Conventional Ventilatory Support vs Extracorporeal Membrane Oxygenation for Severe Adult Respiratory Failure (CESAR) [ISRCTN47279827]. HTA Monograph.
  52. Peek GJ, Elbourne D, Mugford M, Tiruvoipati R, Wilson A, Allen E, Clemens F, Firmin R, Hardy P, Hibbert C, Jones N, Killer H, Thalanany M, Truesdale A. Randomised Controlled Trial of Conventional Ventilatory Support vs Extracorporeal Membrane Oxygenation for Severe Adult Respiratory Failure (CESAR) [ISRCTN47279827]. Lancet 2009 Oct 17; 374(9698): 1351-63.
  53. Csomos A, Varga Sz, Bertolini G, Hibbert C, Sandor J, Capuzzo M, Guidet B on behalf of the Research Group on Health Economics of the European Society of Intensive Care Medicine. Intensive care reimbursement practices: results from the ICUFUND survey. Intensive Care Med. 2010 Oct;36(10):1759-64. doi: 10.1007/s00134-010-1911-8. Epub 2010 May 28.
  54. Pike J, Liu Y, Lee A, Hibbert C, Hoskin B. Impact of walking impairment on healthcare resource utilisation in multiple sclerosis patients. ISPOR International Society for Pharmacoeconomics and Outcomes Research – 20th International Meeting (2015).
  55. Vaidya S, Hibbert C, Kinter E, Boes S. Identification of Key Cost Generating Events for Idiopathic Pulmonary Fibrosis: A Systematic Review. Lung 2017; 195:1-8.
  56. Hague C, Price M. Challenges and Proposed Solutions to Value Assessment and Reimbursement of CAR-T therapies in Europe. Cell & Gene Therapy Insights 2020;6:7:1013-1028.
  57. com. COVID-19: Accelerating digital transformation in the life sciences. Listed contributor. Reuters Events Pharma. August 2020.
  58. Dietrich C, Hague C, Boes S. Solving the problem of financing one-time treatments: Which type of outcomes-based payment models could work best for novel CAR-T therapies in multiple myeloma? A systematic review. Cell & Gene Therapy Insights July 7, 2021.
  59. Groves E, Borget I, Bruns J, Cardone A, Fiteni F, Hadascik B, Hemmings R, Rodriguez Otero P, Hutchings A, Azough A, Hague C, Palmer S. Absence of comparative survival data in health technology assessment of oncology therapies: Multi-stakeholder perspectives on challenges, implications and solutions. Submission to: Expert Opinion in Pharmacoeconomics & Outcomes Research, July 2021.
  60. Hunger M, Bardenheuer K, Passey A, Schade R, Sharma R, Hague C. The value of federated data networks in oncology: what research questions do they answer? Outcomes from a systematic literature review. Value in Health. Dec 2021.
  61. Bardenheuer K, Van Speybroeck M, Hague C, Nikai E, Price M. Haematology Outcomes Network in Europe (HONEUR) – a collaborative, interdisciplinary platform to harness the potential of Real-World Data in Haematology. European Journal of Haematology Accepted April 19, 2022.
  62. Weisel K, Mateos M-V, Vincent L, Martin T, Berdeja JG, Jakubowiak A, Jagannath S, Lin Y, Thilakarathne P, Ghilotti F, Diels J, Haefliger B, Hague C, Gonzalez A, Schecter JM, Gries KS, Strulev V, Nesheiwat T, Pacaud L, Einsele H, Moreau P. P971: Adjusted comparison of patient reported outcomes from CARTITUDE-1 and Locommotion comparing Ciltacabtagene Autoleucel versus Real World Clinical Practice in Triple-Class Exposed Multiple Myeloma. HemaSphere 2022; 6: 861-862.
  63. Maria-Victoria Mateos, Katja Weisel, Thomas Martin, Jesús G. Berdeja, Andrzej Jakubowiak, A. Keith Stewart, Sundar Jagannath, Yi Lin, Joris Diels, Francesca Ghilotti, Nolen J Perualila, Jedelyn Cabrieto, Benjamin Haefliger, Nichola Erler-Yates, Clare Hague, Carolyn C. Jackson, Vadim Strulev, Tonia Nesheiwat, Lida Pacaud, Philippe Moreau, Hermann Einsele; Ciltacabtagene Autoleucel for Triple-Class Exposed Multiple Myeloma: Adjusted Comparisons of CARTITUDE-1 Patient Outcomes Versus Therapies from Real-World Clinical Practice from the LocoMMotion Prospective Study. Blood2021; 138 (Supplement 1): 550. doi: https://doi.org/10.1182/blood-2021-146200.
  64. Mateos MV, Weisel K, Martin T, Berdeja JG, Jakubowiak A, Stewart AK, Jagannath S, Lin Y, Diels J, Ghilotti F, Thilakarathne P, Perualila NJ, Cabrieto J, Haefliger B, Erler-Yates N, Hague C, Jackson CC, Schecter JM, Strulev V, Nesheiwat T, Pacaud L, Einsele H, Moreau P. Adjusted comparison of outcomes between patients from CARTITUDE-1 versus multiple myeloma patients with prior exposure to PI, IMiD and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practice. Haematologica. 2022 Dec 22. doi: 10.3324/haematol.2022.280482. Epub ahead of print. PMID: 36546453.
  65. Walder A, Csanadi M, Pitter JG, Agh T, Andersone L, Hague C, Rodrigues GM, Redai E, Voko Z, Boes S. Genetic mutational testing in CLL patients in the routine care of eight EU member states. ISPOR Europe Abstract (accepted).

Department of Health Reports (maiden name Hibbert)

  1. Deliverable 1: Evaluation of Sheffield Health-Care Costing System I – Configuration and Deployment. A J Wilson, D L Edbrooke, C Hibbert, A Mann, V Stevens. April 1996
  2. Deliverable 2: Techniques and Tools for Budget Management in the ICU. A J Wilson, C Hibbert, V G Stevens, D L Edbrooke. April 1996
  3. Deliverable 3: Evaluation of Proposed Healthcare Resource Groups (HRGs) for Intensive Care Units (ICUs). A J Wilson, VG Stevens, D L Edbrooke, A J Mann, C L Hibbert. October 1997.
  4. The Provision of High Dependency Units in England – The Costs and Benefits of Development and Implementation. A Report from the Medical Economics & Research Centre, Sheffield to the Department of Health, February 1996.
  5. Exploration of the potential uses of the Augmented Care Period Data Set. Medical Economics and Research Centre, Sheffield. April 1998.
  6. Evaluation of the number of organ systems supported (ORGSUP) as a measure of activity. Medical Economics and Research Centre, Sheffield. April 1998.
  7. Problems with the collection of the Augmented Care Period Data Set. Medical Economics and Research Centre, Sheffield. April 1998
  8. Edbrooke DL, Hibbert CL, Corcoran M, Bright N. A detailed analysis of the type and duration of organ support data for intensive care patients and development of appropriate cost-weightings for the Augmented Care Period Data Set. Research Report for the National Case-Mix Office, December 1998.
  9. Edbrooke DL, Hibbert CL, Corcoran M. Adult Intensive Care Review: An International Perspective. Report for the NHS Executive, London. August 1999.
  10. Edbrooke DL, Hibbert CL. Future provision of critical care beds in Sheffield for the next 5 years. Report for Sheffield Health, Royal Hallamshire and Northern General Hospitals. August 1999.
  11. Hibbert CL, Coates E, Brazier J, Morris J. Development of Healthcare Resource Groups for adult critical care. Report for the NHS Information Authority, Jan 2004.

Conference Papers (maiden name Hibbert)

  1. Hibbert CL. Equipment utilisation in Intensive Care.  National study day sponsored by the British Association of Critical Care Nurses (BACCN), June 1996.
  2. Smith S, Stevens VG, Edbrooke DL, Wilson AJ, Hibbert CL, Mann AJ. Cost implications for intensive care of the ageing of the population.  Presented at the 9th European Congress on Intensive Care Medicine, Glasgow, September 1996.
  3. Edbrooke DL, Wilson AJ, Stevens, Hibbert CL, Mann AJ, Kingsley J. The provision of high dependency units in England – the cost and benefits of development and implementation.  Presented at the 9th European Congress on Intensive Care Medicine, Glasgow, September 1996.
  4. Wilson AJ, Stevens VG, Hibbert CL, Mann AJ, Edbrooke DL. Validation of HRGs for Intensive Care. Presented at The National Casemix Conference, Birmingham, October 1996.
  5. Stevens VG, Edbrooke DL, Hibbert CL, Wilson AJ. Integrated clinical and cost audit in the ICU. Presented at Healthcare Computing Conference, Harrogate, March 1997.
  6. Edbrooke DL, Hibbert CL. Costing methodologies in the Intensive Care Unit. University of Alberta, Edmonton. Anaesthetic and Intensive Care Division. May 1997.
  7. Edbrooke DL, Hibbert CL. Costs of Intensive Care. 10th Annual Congress of the European Society of Intensive Care Medicine, Paris, September 1997.
  8. Hibbert CL, Edbrooke DL. An economic model for evaluating the cost impact of new drug therapies in intensive care patients. Presented at the 10th Annual Congress of the European Society of Intensive Care Medicine, Paris, 7-10th September 1997.
  9. Edbrooke DL, Hibbert CL, Kingsley JM, Wilson AJ, Stevens VG, Smith S, Loynes RM. The costs of severe sepsis in a UK adult general intensive care unit. Presented at the 10th Annual Congress of the European Society of Intensive Care Medicine, 7-10th September 1997.
  10. Edbrooke DL, Hibbert CL. A Standardised Method for Costing Adult General Intensive Care Units (ICUs) in the UK. Presented at the 10th Annual Congress of the European Society of Intensive Care Medicine, 7-10th September 1997.
  11. Hibbert CL, Edbrooke DL. A cost-analysis of ICU patients who receive loss-air loss bed therapy and the additional costs involved. Oral presentation at the 11th Annual Congress of the European Society of Intensive Care Medicine, Stockholm 6-9th September 1998.
  12. Edbrooke DL, Lindley EJ, Stevens VG, Wilson AJ, Hibbert CL. Which factors can be used to accurately predict the costs of care for intensive care patients? Oral presentation at the 11th Annual Congress of the European Society of Intensive Care Medicine, Stockholm 6-9th September 1998.
  13. Hibbert CL, Kingsley JM, Edbrooke DL. A study of nursing time and associated costs spent positioning patients in Intensive Care. Oral presentation at the 11th Annual Congress of the European Society of Intensive Care Medicine, Stockholm 6-9th September 1998.
  14. Mills GH, Hibbert CL, Edbrooke DL. Can the Therapeutic Intervention Scoring System be used to accurately reflect the daily costs of care for individual patients on the Intensive Care Unit? Oral presentation at the 11th Annual Congress of the European Society of Intensive Care Medicine, Stockholm 6-9th September 1998.
  15. Edbrooke DL, Hibbert CL. Cost Effectiveness in Critical Care. Intensive Care Forum: Stocktake of Adult Intensive Care, 13 February 1998. NHS Executive, Richmond House.
  16. Edbrooke DL, Hibbert CL Cost and cost-effectiveness in intensive care. 10th European congress of Anaesthesiology – Frankfurt, July 1998.
  17. Edbrooke DL, Hibbert CL. A European Costing Methodology. 11th Annual Congress of the European Society of Intensive Care Medicine, Stockholm, September 1998.
  18. Edbrooke DL, Hibbert CL. Cost-effectiveness in Intensive Care. 11th Annual Congress of the European Society of Intensive Care Medicine, Stockholm, September 1998.
  19. Edbrooke DL, Hibbert CL, Mills GH. Does it make sense to correlate TISS points against ICU costs? Austrian Society of Anaesthesiology Resuscitation and Intensive Care Medicine, Vienna October 1998.
  20. Hibbert CL. Costs associated with specialised bed therapy. Oral presentation at the British Association of Critical Care Nurses, October 1998.
  21. Edbrooke DL, Hibbert CL. Economical aspects of intensive care. Belgium Society of Intensive Care and Emergency Medicine, Leuven, November 1998.
  22. Edbrooke DL, Hibbert CL. Meet the expert – How to evaluate the costs of ICU. 7th Portuguese National Congress of Intensive Care, Lisbon, November 1998.
  23. Edbrooke DL, Hibbert CL. Can we afford Intensive Care? Key note address. 19th International Symposium on Intensive Care and Emergency Medicine, Belgium, March 1999.
  24. Edbrooke DL, Hibbert CL. How I calculate the costs of my ICU. 19th International Symposium on Intensive Care and Emergency Medicine, Belgium, March 1999.
  25. Hibbert CL. Antibiotic costing in the Intensive Care Unit, 4th Congress of the European Association of Hospital Pharmacists. Audit and Evaluation of Antibiotic Prescribing. Nice, France 17-19 March 1999 (Invited speaker).
  26. Hibbert CL, Edbrooke DL. The Augmented Care Period Data Set – Can it be used for costing intensive care patients? Trent Institute for Health Services Research, 4th Annual Conference, April 1999.
  27. Edbrooke DL, Hibbert CL Costing in Intensive Care. 20th International Symposium on Current Problems in Emergency and Intensive Care Medicine, Münster August 1999.
  28. Hibbert CL. Costing an ICU bed. Intensive Care Nursing Symposium. The Bloomsbury Institute of Intensive Care Medicine. London 30th September 1999. (Invited speaker).
  29. Edbrooke DL, Hibbert CL Costing for the uninterested. 12th Annual Congress of the European Society of Intensive Care Medicine, Berlin, October 1999.
  30. Hibbert CL, Edbrooke DL, Corcoran M. Is organ support the answer to costing care in the ICU? 12th Annual Congress of the European Society of Intensive Care Medicine, Berlin, October 1999.
  31. Hibbert CL. Cost Block Methodology. National Cost Block Meeting. Sheffield November 1999 (Invited speaker).
  32. Hibbert CL. International Comparisons of Intensive Care. National Expert Group Meeting, London 27th January 2000.
  33. Edbrooke DL, Hibbert CL. Costs, reimbursement and profits generated in a private ICU. Are there new opportunities? 6th Edition of Hospital CUF Annual Meeting, Lisbon, Portugal, June 2000.
  34. Regional ICU Meeting in Belfast, sponsored by Astra Zeneca Hosted a debate on cost-effectiveness issues in intensive care. 13th June 2000.
  35. Edbrooke DL, Ridley SA, Hibbert CL, Corcoran MC. Variation in expenditure between adult general ICUs in the UK. 13th Annual Congress of the European Society of Intensive Care Medicine, Rome, October 2000.
  36. Hibbert CL. Modelling of critical care provision. South West Intensive Care Society. Exeter, October 2000.
  37. Hibbert CL. How to audit outreach services. Critical Care Outreach Team Workshop. North Trent Critical Care Network, Swallow Hotel, Rotherham, January 2001.
  38. Hibbert CL. The Augmented Care Period Data Set. North Trent Audit Training Programme, Rutland Hotel, Sheffield Feb 2001.
  39. Hibbert CL. Economic implications of early feeding with enteral nutrition. Novartis Consumer Health, UK. March 2001.
  40. Hibbert CL. Modelling of critical care services. Trent Regional Learning Network, Derby, 4th April 2001.
  41. Hibbert CL. The National Cost Block Programme: What is involved in participation? National Meeting, Ashby de la Zouch, Leicestershire, 9th April 2001.
  42. Hibbert CL. Development of the cost block method. European Programme for Resource Use in Critical Care (EPOC) Meeting. Budapest, April 2001.
  43. Hibbert CL. Health economic evaluation of the adult ECMO clinical trial. National launch Meeting, London, 25th April 2001.
  44. Hibbert CL. Presentation on the Critical Care National Cost Block Programme. Paediatric Intensive Care Society Directors’ Meeting, Leicester, 26th April 2001.
  45. Hibbert CL. Cost implications of the use of IMPACTÒ in the critically ill. Novartis Consumer Health, Stockholm, 3rd May 2001.
  46. Hibbert CL. Patient-level costing of adult intensive care: A systematic review of the literature. Sheffield Teaching Hospitals NHS Trust Research Forum. Cancer Research Forum, 20th June 2001.
  47. Edbrooke DL, Coates E, Hibbert CL. Modelling of critical care. NPAT Meeting, 29th June 2001.
  48. Hibbert CL, Edbrooke DL, Coates EJ. Development of a discrete event simulation model to predict bed requirements for critical care. 14th Annual Congress of the European Society of Intensive Care Medicine, Geneva, Oct 2001.
  49. Coates EJ, Hibbert CL, Edbrooke DL. A cost-effectiveness study of enteral immune modulating nutrition in intensive care patients. 14th Annual Congress of the European Society of Intensive Care Medicine, Geneva, Oct 2001.
  50. Hibbert CL. Presentation of PhD project. Graduate Conference 2001 at the School of Health and Related Research, University of Sheffield, November 2001.
  51. Hibbert CL. “ICU Costs: A systematic review of costing methods”. 22nd International Symposium on Intensive Care and Emergency Medicine, Brussels Congress Center – March 19-22, 2002.
  52. Hibbert CL. Costing methodology for ICU and hospital resources for the CESAR Trial, CESAR Collaborators’ Meeting, London, January 2003.
  53. Hibbert CL. The Critical Care HRG Study. National Dataset Workshop in Critical Care, London, February 2003.
  54. Hibbert CL. The Critical Care HRG Study. ESICM Research Group on Cost-Effectiveness Meeting, Brussels, March 2003.
  55. Hibbert CL. The Critical Care HRG Study. North Manchester Clinical Network Meeting, Manchester, March 2003.
  56. Hibbert CL. The Critical Care HRG Study. Mid-Trent Clinical Network Meeting, Derby, March 2003
  57. Hibbert CL. The Critical Care HRG Study. Lincoln County Hospital, March 2003.
  58. Hibbert CL. The Critical Care HRG Study : A Methodology Workshop. 4th Annual Case-Mix Conference, London, April 2003.
  59. Hibbert CL. Economic Outcome Evaluation. Second Annual Cambridge Colloquium sponsored by the International Sepsis Forum, Cambridge, Queen’s College, UK, June 28-30, 2003 (Invited Speaker).
  60. Hibbert CL. Cost-efficacy vs. cost-effectiveness. Presentation to the ESICM Research Group on Health Economics, Oct 2007.
  61. Hague CL. EU+ Market Access. Annual International Regulatory Affairs and SABR Affiliate & Distributor Meeting 2014. 21-23rd October 2014, Barcelona, Spain.
  62. Hague CL. Early Payer Advice Workshop, Biogen Idec. Moderator for Session Entitled “Overview of Historical / Established Advice Channels. Launch Event: Biogen Idec HQ, Cambridge, Boston, 20 November 2014.
  63. Hague CL. Relative efficacy assessments from a Manufacturer Perspective. 1st EAPM Personalized Medicines Conference, Belfast, November 2017 (Invited Speaker)
  64. Hague CL. Eyeforpharma keynote presentation, April 1, 2020.
  65. Hague C. How Patient Engagement Can Foster Access Through Improved Affordability? Access & Affordability Considerations in the Pharmaceutical Industry. Patient Engagement Open Forum, EUPATI. Sept 2020.
  66. Hague C. Virtual Evidence, Pricing and Access Congress 2021. Panel Discussion: What can be done to improve collaboration between patients and pharma? 14th April 2021.
  67. Hague C. Webinar organized by REUTERS on “Embedding patient value as your access differentiator” with Takeda, Sobi and Kyowa Kirin. July 1, 2021.
  68. Hague C. POLITICO Webinar on “Improving Europe’s Health Technology Assessments” 13th July 2021: 13.00-14.00.
  69. Hague C. Keynote speaker. Phco21. 12th Pharma & health conference. This was a key Health Policy Conference in Greece, its audience spanning from Pharma Industry Executives to National Payer & MoH & government representatives, PAG members and health journalists / media. July 15th
  70. Hague C, Verhoef M, Kundzewicz A, Riol R. Panel: The digital disruption of market access. Eye for Pharma 2021, October 21 2021.
  71. Mateos Manteca MV, Weisel K, Moreau P, Martin T, Berdeja JG, Jakubowiak A, Stewart K, Jagannath S, Lin Y, Diels J, Ghilotti F, Perualila NJ, Cabrieto J, Hafliger, Erler-Yates N, Hague C, Jackson CC, Strulev V, Nesheiwat T, Pacaud L, Einsele H. Ciltacabtagene autoleucel for triple-class exposed multiple myeloma: adjusted indirect comparisons of CARTITUDE-1 outcomes versus therapies from real-world clinical practice from the LocoMMotion prospective cohort. ASH Abstract 2021.
  72. Cameron C, Valluri S, Hague C. Can Single-Arm Trials of CAR-T Therapies Meet the Evidence Requirements of Global Health Technology Assessment Agencies? Are There Innovative Ways to Address the Comparative Evidence Needs? for Virtual ISPOR Europe 2021, 1 – 3 December 2021.
  73. Hague C. How pharma can inform patients, advocates & carers in using the HTAi summary of information for patients (SIP) for Thursday 24th March 2022 at 15.40-16.00. World Evidence, Pricing and Access Congress 2022 – 22-24th March 2022 – Amsterdam, Beurs Van Berlage.
  74. Hague C. Panel Discussion. Ensure Greater Transparency and Apply Real World Data to Support Market Access. RWE and Market Access Symposium. April 11-12, 2022.
  75. Hague C. Understanding the role that Federated Data Networks (FDNs) play in enabling key research questions to be addressed quickly and cost effectively. RWE and Market Access Symposium. April 11-12, 2022.
  76. Hague C. The importance of prioritizing value-based health care to optimize patient outcomes and ensure sustainability of health systems: Challenges and Opportunities. ARC Summit, Israel, June 28th
  77. Hague C. Panel Member: Change healthcare from within: Drive trust in the robustness of RWD and RWE, within your organization. Reuters Events Pharma Europe conference, Oct 12th 2022.